那格列奈(唐力~)在降糖达标中的地位——中国专家座谈纪要2007 被引量：2

导出

摘要 2007年6月,中国著名的糖尿病专家们会聚北京举行座谈,讨论了在临床工作中进一步促进降糖达标的重要性和几点措施,特别是对于新型的氨基酸类降糖药物那格列奈(唐力^(?))在降糖达标中的地位进行了讨论。与会专家有:潘长玉教授,陈家伟教授,傅祖植教授,纪立农教授,陆菊明教授,朱大龙教授,郭晓蕙教授,洪天配教授,姬秋和教授,彭永德教授等。现将会议讨论的主要内容摘录如下:

作者陈家伟傅祖植刘昕

机构地区南京医科大学第一附属医院内分泌科中山大学附属第二医院内分泌科诺华制药有限公司

出处《中华内分泌代谢杂志》 CAS CSCD 北大核心 2007年第6期593-596,共4页 Chinese Journal of Endocrinology and Metabolism

关键词降糖药物那格列奈专家中国唐力临床工作氨基酸类糖尿病

分类号 R587.1 [医药卫生—内分泌] R977.15 [医药卫生—药品]

引文网络
相关文献

参考文献29

1World Health Organization. Country and regional data. Available at: http ://www. who. int/diabetes/facts/world_figures/en/.
2International Diabetes Federation. 2005 : Global Guideline for Type 2 Diabetes. available at: http://www, idf. org/webdata/docs/IDF%20GGT2 D. pdf/.
3潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量：193
4Louis M, Helene L, Claude C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbAlc. Diabetes Care, 2003,26:881-885.
5纪立农.糖尿病的强化治疗策略——精细降糖、安全达标[J].国外医学（内分泌学分册）,2004,24(4):274-275. 被引量：48
6Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest, 2000, (Suppl 2) :3-11.
7Ward WK, Beard JC, Halter JB, et al. Pathophysiology of insulin secretion in diabetes meUitus. Adv Exp Med Biol, 1985,189:137-158.
8Campbell IW. Nateglinide-current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract, 2005,59 : 1218- 1228.
9Gtibble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications, 2003,17 (2 Suppl) : 11-15.
10Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabet Med, 1996,13(9 Suppl 6) :S151-S155.

二级参考文献10

1黄晓程,贤晓丽.新型降糖药那格列奈的药理作用和临床应用[J].中国新药与临床杂志,2005,24(2):148-150. 被引量：29
2陆小平,王闻博,晏玲,龚雄辉,崔岚,刘悦,张小苏,李秀梅,王鸿玉.吸烟对男性2型糖尿病患者血糖控制的影响[J].中华内分泌代谢杂志,2003,19(4):294-295. 被引量：28
3张家庆.血糖及其他体液葡萄糖测定进展[J].中华内分泌代谢杂志,2003,19(4):333-335. 被引量：59
4HU S,WANG S,FANELLI B,et al.Pancreatic beta-cell K (ATP) channel activity and membrane-binding studies with nateglinide:a comparison with sulfonylureas and repaglinide[J].J Pharmacol Exp Ther,2000,293(2):444-452.
5HANEFELD M,BOUNTER KP,DIKISION S,et al.Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia[J].Diabetes Care,2000,23(2):202-207.
6OWENS DR,ZINMAN B,BOLLI GB.Insulins today and beyond[J].Lancet,2001,358(9283):739-746.
7ROSENSTOCK J,SCHWARTZ SL,CLARK CM Jr,et al.Basal insulin therapy in type 2 diabetes:28-week comparison of insulin glargine (HOE 901) and NPH insulin[J].Diabetes Care,2001,24(4):631-636.
8HU S,WANG S,DUNNING BE.Tissue selectivity of antidiabetic agent nateglide:study on cardiovascular and beta-cell K (ATP) channels[J].J Pharmcol Exp Ther,1999,291(3):1372-1379.
9全国糖尿病防治协作组,潘孝仁,杨文英,刘娟,郑旭,王芃,刘铨之.1994年中国糖尿病患病率及其危险因素[J].中华内科杂志,1997,36(6):384-389. 被引量：424
10国家"九五"攻关计划糖尿病研究协作组.中国12个地区中老年人糖尿病患病率调查[J].中华内分泌代谢杂志,2002,18(4):280-284. 被引量：264

共引文献243

1张辰,陈玉芳,刘波.2型糖尿病实施重组甘精胰岛素联合重组赖脯胰岛素的治疗效果分析[J].世界最新医学信息文摘,2020(99):128-129.
2刘成贵,齐晏.糖尿病患者药物治疗依从性影响因素分析[J].中国医疗前沿（学术版）,2008,3(2). 被引量：3
3李爱先,魏兆甫.甘精胰岛素的临床应用[J].中国现代药物应用,2009,3(4):146-147. 被引量：2
4王小婕,李学善.17例老年干部保健对象糖尿病控制情况分析[J].中国老年保健医学,2006,4(3):36-37. 被引量：4
5朱敏,陈耀,陈煜宇.诺和锐30短期治疗2型糖尿病的体会[J].中国医学工程,2011,19(2):28-29.
6贾伟平.血糖控制达标是预防糖尿病并发症的关键[J].上海医学,2005,28(1):1-3. 被引量：46
7姜素英,左玉华,张和平,徐文,刘芳,贾伟平.社区糖尿病治疗达标现状分析[J].上海医学,2005,28(1):30-32. 被引量：31
8高维国,董砚虎,南海荣.青岛地区2型糖尿病患病危险因素的调查与分析[J].中华内分泌代谢杂志,2005,21(1):65-66. 被引量：14
9郑春毅.糖化血红蛋白的测定及临床应用观察[J].中国误诊学杂志,2005,5(9):1656-1657.
10申红.胰岛素泵治疗2型糖尿病的临床体会[J].临床医药实践,2005,14(8):622-623.

同被引文献9

1潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量：193
2World Health Organization.Definition,Diagnosis and Classification of Diabetes Mellitus and its Complications:Report of a WHO Consultation.Partl:Diagnosis and Classification of Diabetes Mellitus.Geneva,World Health Org,1999:1.
3World Health Organization.Country and regional data.Availableat; http://www.who.int/diabetes/facta/world.figures/cn/.
4Louis M,Helene L,Claude C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:Variations with increasing levels of HbA1c.Diabetes Care,2003,26:881.
5Kikichi M.Modulation of insulin secretion in non-insulin-dependent diabetes mellitusby two novel oral hypoglycaemic agents,NN623 and A4166.Diabet Med,1996,13:S151.
6Yki-Jarvinen H,Dressier A,Ziemen M,H0E901/3002 Study Group:Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compare with bedtime NPH insulin during combination therapy in type 2 diabetes.Diabetes Care,2000,23:1130.
7Yki-J n rvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post dinner glucose control with bedtime insulin alargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J]. Diabetes Care, 2000,23(8) : 1130-1136.
8McSorley PT,Bell PM,iacobsen LV,et al.Twice dailg biphasic insulin aspart 30 versus biphasic human insulin 30:a double blind crossover study in adults with type 2 diabetes mellitus[J]. Clin Ther,2002,24(4): 530 539.
9杨文英.重视预防，规范管理——2007年版《中国2型糖尿病防治指南》[J].中华内分泌代谢杂志,2008,24(2):121-122. 被引量：121